
|Videos|June 4, 2021
Efficacy, Safety of Nivolumab Plus Cabozantinib Versus Sunitinib for Patients With Advanced Renal Cell Carcinoma
Andrea Apolo, MD, a Lasker clinical research scholar and head of the Bladder Cancer Section at the National Cancer Institute, discusses her presentation on nivolumab plus cabozantinib versus sunitinib for aRCC.
Advertisement
Pharmacy Times interviewed Andrea Apolo, MD, a Lasker clinical research scholar and head of the Bladder Cancer Section at the National Cancer Institute, on her presentation at the 2021 ASCO Annual Meeting on nivolumab plus cabozantinib versus sunitinib for advanced renal cell carcinoma (aRCC).
During the discussion, Apolo detailed some of the findings of the phase 3 trial around the efficacy and safety of nivolumab plus cabozantinib versus sunitinib for patients with aRCC.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Beyond Off-Label: How Auvelity's Approval Changes Agitation Management in Alzheimer Disease
2
What Does the FDA Advisory Committee’s Vote on 7 Peptides Mean for Pharmacy Practice?
3
FDA Approves SimpleScreen CRC Blood Test for Colorectal Cancer Screening
4
What the Peptide Vote Actually Changes at My Counter (Hint: Not Much, Yet)
5











































































































